Axovant Sciences (NYSE: AXON) recently received a number of ratings updates from brokerages and research firms:

  • 10/9/2017 – Axovant Sciences was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “strong-buy” rating. They now have a $8.00 price target on the stock. According to Zacks, “Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. Its product candidate includes RVT-101 which is in different clinical trial for the treatment of Alzheimer’s disease and other forms of dementia. Axovant Sciences Ltd. is based in Hamilton, Bermuda. “
  • 10/6/2017 – Axovant Sciences had its “sell” rating reaffirmed by analysts at Chardan Capital. They now have a $3.00 price target on the stock.
  • 10/5/2017 – Axovant Sciences was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 9/27/2017 – Axovant Sciences had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $12.00 price target on the stock.
  • 9/27/2017 – Axovant Sciences had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
  • 9/26/2017 – Axovant Sciences was downgraded by analysts at Robert W. Baird from an “outperform” rating to a “neutral” rating. They now have a $6.00 price target on the stock, down previously from $29.00.
  • 9/26/2017 – Axovant Sciences was downgraded by analysts at UBS AG from an “outperform” rating to a “market perform” rating.
  • 9/26/2017 – Axovant Sciences was downgraded by analysts at Piper Jaffray Companies from an “overweight” rating to a “neutral” rating. They now have a $9.00 price target on the stock, down previously from $32.00.
  • 9/26/2017 – Axovant Sciences had its “outperform” rating reaffirmed by analysts at JMP Securities. They now have a $19.00 price target on the stock, down previously from $36.00.
  • 9/26/2017 – Axovant Sciences was downgraded by analysts at Oppenheimer Holdings, Inc. from an “outperform” rating to a “market perform” rating.
  • 9/26/2017 – Axovant Sciences had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $25.00 price target on the stock, down previously from $30.00.
  • 9/26/2017 – Axovant Sciences had its “outperform” rating reaffirmed by analysts at Evercore ISI. They now have a $9.00 price target on the stock, down previously from $30.00.
  • 9/26/2017 – Axovant Sciences was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 9/25/2017 – Axovant Sciences had its “buy” rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $30.00 price target on the stock.
  • 9/23/2017 – Axovant Sciences was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 9/23/2017 – Axovant Sciences had its “sell” rating reaffirmed by analysts at Chardan Capital. They now have a $3.00 price target on the stock.
  • 9/15/2017 – Axovant Sciences was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 9/14/2017 – Axovant Sciences had its “sell” rating reaffirmed by analysts at Chardan Capital. They now have a $8.00 price target on the stock.
  • 9/8/2017 – Axovant Sciences is now covered by analysts at Evercore ISI. They set an “outperform” rating and a $30.00 price target on the stock.
  • 8/25/2017 – Axovant Sciences was given a new $40.00 price target on by analysts at Jefferies Group LLC. They now have a “buy” rating on the stock.
  • 8/19/2017 – Axovant Sciences was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.

Axovant Sciences Ltd (NYSE AXON) opened at 6.54 on Thursday. Axovant Sciences Ltd has a one year low of $6.13 and a one year high of $27.98. The firm’s 50-day moving average price is $14.60 and its 200 day moving average price is $14.60. The firm’s market cap is $703.21 million.

Axovant Sciences (NYSE:AXON) last posted its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.65) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by ($0.12). On average, equities research analysts forecast that Axovant Sciences Ltd will post ($2.02) EPS for the current year.

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Receive News & Ratings for Axovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.